Mandate

Vinge advises Cinclus Pharma in connection with a capital raising

Vinge has advised the pharmaceutical development company Cinclus Pharma in connection with a capital raising of approximately SEK 250 million by way of a directed share issue to several new investors and current shareholders.

The purpose of the share issue is to fund the further clinical development of X842, a clinical-stage drug candidate for the treatment of gastroesophageal reflux disease (GERD).

Vinge’s team consisted primarily of Dain Hård Nevonen, Kristina Ekberg, Amanda Knutsson and Fredric Reissmüller.

Related

Vinge advises Right Side Group, a portfolio company of Alder, in connection with the acquisition of Brandkonsultbyrån i Sverige

Brandkonsultbyrån in Sweden is a technical consultant specialising in structural fire protection, evacuation safety and risk management. The acquisition strengthens the group’s position as a leading player in fire, risk and safety in the Nordic region.
April 17, 2026

Vinge advises Vidia Climate Fund I in connection with the acquisition and acquisition financing of ABEKA El & Kraftanläggningar AB

Vinge has acted as legal adviser to Vidia Climate Fund I in connection with the acquisition and acquisition financing of ABEKA El & Kraftanläggningar AB from Bravida and certain minority shareholders. ABEKA El & Kraftanläggningar AB is a highly specialized electrical grid services and project management provider.
April 17, 2026

Vinge advises Lagercrantz Group on the acquisition of Nivex Topsafe

Lagercrantz Group AB (publ) has acquired the shares in Nivex Topsafe AB, a leading player in the Swedish market for secure storage solutions such as security and fire-rated safes as well as secure rooms, with operations in Sweden and Poland.
April 17, 2026